SOON:SIXSonova Holding AG Analysis
Data as of 2026-03-13 - not real-time
CHF 194.10
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Sonova Holding AG (SOON.SW) is trading at CHF 194.1, which sits below its 20‑day (CHF 196.3), 50‑day (CHF 205.5) and 200‑day (CHF 220.6) simple moving averages, signaling a bearish price trend. The RSI of 43.7 suggests the stock is not yet oversold, while the MACD line has just crossed above its signal line, producing a modest bullish histogram of 0.11 and hinting at a possible short‑term bounce. Volume is increasing and the 30‑day volatility is high at 31.3%, but the computed beta of 0.35 indicates low systematic risk relative to the market. Support sits at CHF 187.35 and resistance at CHF 204.90, giving the price a narrow trading range with limited upside in the near term.
Fundamentally, Sonova delivers strong profitability with a gross margin of 71.8%, operating margin of 14.3% and ROE of 22.2%, while revenue is flat year‑over‑year (‑1%). The forward P/E of 17.7 is well below the industry average of 26.2, and the dividend yield of 2.27% is supported by a 50.5% payout ratio and solid cash flow. Analysts average a target price of CHF 229, implying roughly 18% upside, yet the DCF fair value of CHF 152.2 suggests the current market price may be overvalued. The company’s moderate debt‑to‑equity (60.5%) and healthy free cash flow further underpin its financial stability.
Fundamentally, Sonova delivers strong profitability with a gross margin of 71.8%, operating margin of 14.3% and ROE of 22.2%, while revenue is flat year‑over‑year (‑1%). The forward P/E of 17.7 is well below the industry average of 26.2, and the dividend yield of 2.27% is supported by a 50.5% payout ratio and solid cash flow. Analysts average a target price of CHF 229, implying roughly 18% upside, yet the DCF fair value of CHF 152.2 suggests the current market price may be overvalued. The company’s moderate debt‑to‑equity (60.5%) and healthy free cash flow further underpin its financial stability.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below all major SMAs indicating bearish bias
- Bullish MACD crossover and rising volume
- Proximity to support level at CHF 187.35
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Forward P/E of 17.7 versus industry average of 26.2
- Analyst target price around CHF 229 (+18% upside)
- Stable dividend yield of 2.27% with 50% payout ratio
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong ROE (22%) and cash flow generation
- Diversified global footprint reducing geographic concentration
- Current price above DCF fair value, limiting upside potential
Key Metrics & Analysis
Financial Health
Revenue Growth-1.00%
Profit Margin13.53%
P/E Ratio22.3
ROE22.17%
ROA8.29%
Debt/Equity60.51
P/B Ratio4.8
Op. Cash FlowCHF819.8M
Free Cash FlowCHF740.1M
Industry P/E26.2
Technical Analysis
TrendBearish
RSI43.7
SupportCHF 187.35
ResistanceCHF 204.90
MA 20CHF 196.29
MA 50CHF 205.54
MA 200CHF 220.57
MACDBullish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair ValueCHF 152.19
Target PriceCHF 228.06
Upside/Downside17.49%
GradeFair
TypeBlend
Dividend Yield2.27%
Risk Assessment
Beta0.35
Volatility31.30%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.